Programs

Mucosis’s lead program SynGEM® seeks to develop a new mucosal vaccines to prevent respiratory syncytial virus vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against RSV in vulnerable people, such as elderly and children. Mucosis also runs research programs aimed at the development of mucosal vaccines to prevent pneumococcal related diseases, and an oral vaccine to prevent bacterial diarrhea (shigella/etec).  These programs build upon the success of the Mucosis FluGEM® which achieved proof-of-concept for the Mimopath platform.

The development phases of the Mucosis programs

research programs

22.05.14 Mucosis receives financial support from the Dutch government for its SynGEM® program
more >

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >